U.S. Diabetes Drugs Market Size, Share & COVID-19 Impact Analysis, By Drug Class (Insulin, DPP-4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors, and Others), By Diabetes Type (Type 1 and Type 2), By Route of Administration (Oral, Subcutaneous, and Intravenous), By Distribution Channel (Online Pharmacies, Hospital Pharmacies, and Retail Pharmacies), and Country Forecast, 2023-2030

The U.S. diabetes drugs market size was worth USD 30.47 billion in 2022 and is projected to grow at a CAGR of 7.6% during the forecast period.

The prevalence of diabetes is increasing across the U.S. owing to poor diet, lack of physical activity, sedentary lifestyle, and obesity in all age groups among the population. This scenario has led to an increased demand for advanced diabetes drugs, further propelling market growth.

• As per statistics published by the Census Bureau in November 2022, about 37 million Americans, including adults and youth, suffer from diabetes.

The COVID-19 pandemic had a negative impact on the market progress in 2020, owing to a decline in the sales of diabetes drugs across retail channels and disruptions in the supply chain of these drugs across the globe.

U.S. Diabetes Drugs Market Trends

Rise in Presence of Biosimilars Across the Country

The demand for cost-effective diabetes drugs is increasing among the population owing to the high cost of conventional drugs used for the treatment of this ailment. Thus, several key players are now focusing on introducing safe, high-quality, and biologically similar products nationwide for treating diabetes.

• In April 2023, Lilly launched its insulin glargine biosimilar, Rezvoglar (insulin glargine-aglr), in the U.S. market for the treatment of diabetes.

Therefore, the rising introduction of biosimilar drugs by key players and the rise in patient awareness will aid the U.S. diabetes drugs market growth.

U.S. Diabetes Drugs Market Growth Factors

Rising Use of Inorganic Strategies by Industry Players to Augment Market Development

The leading market players in the U.S. are emphasizing the development of advanced drugs that are similar to traditional diabetes drugs, such as insulin glargine, by acquiring other key players in the market.

• In November 2022, Biocon Biologics Ltd., a subsidiary of Biocon Ltd., announced the acquisition of the global biosimilar business of its partner Viatris Inc. The collaboration resulted in the launch of an interchangeable biosimilar semglee (insulin glargine-yfgn) injection in November 2021. The injection will help control high blood sugar in adult and pediatric patients with type 1 diabetes and adults with type 2 diabetes.

Such initiatives will further expand the existing diabetes drugs product portfolio of key players, thereby propelling market growth.

RESTRAINING FACTORS

High Cost of Diabetes Drugs to Restrain Market Growth

The financial burden of diabetes treatment on the U.S. population is high. Moreover, prices of advanced diabetes drugs, such as insulin, are rising due to the high costs sustained by key players from introducing incremental improvements to the processing of these drugs.

• According to an article published by PETERSON-KFF Health System Tracker in August 2023, the cost of Ozempic drugs in the U.S. is around USD 936 compared to the U.K. and France, where the price of these medicines is USD 100 and USD 83, respectively.

Thus, the high price of diabetes treatment in the U.S. compared to other developed countries might limit the adoption of these drugs in the market.

The number of people diagnosed with diabetes in the U.S. was higher than that of other developed countries, such as the U.K. (3.5 million) and Australia (1.3 million) in 2022.

U.S. Diabetes Drugs Market Segmentation Analysis

By Drug Class Analysis

Based on drug class, the market is segmented into insulin, DPP-4 inhibitors, GLP-1 receptor agonists, SGLT2 inhibitors, and others.

The GLP-1 receptor agonists segment held a larger market share in 2022 owing to the increasing demand for and sales of these drugs among the population due to their extensive advantages over conventional insulins. These include improved blood sugar control and weight loss.

• As per the Novo Nordisk A/S annual report published in 2022, the sales of Ozempic drugs generated USD 5,994.4 million in revenue in 2022, an increase of 70.2% from 2021 in the U.S.

By Diabetes Type Analysis

Based on diabetes type, the market is segmented into type 1 diabetes and type 2 diabetes.

The type 2 diabetes segment held a dominant share of the market. The segment’s higher share was attributed to an increase in the prevalence of type 2 diabetes among the adult and young population across the country compared to type 1 diabetes.

• As per data published by the Centers for Disease Control and Prevention (CDC) in 2021, about 90-95% of the diabetic population in the U.S. suffered from type 2 diabetes.

By Route of Administration Analysis

On the basis of route of administration, the market is segmented into oral, subcutaneous, and intravenous.

The subcutaneous segment held a larger share of the U.S. market in 2022. This was due to increased administration of insulin through the subcutaneous route and a rise in self-administration of insulin among diabetic patients.

• According to an article published by the NCBI in February 2023, subcutaneous is the most common route of insulin administration as it is easy to administer and requires minimal skills.

By Distribution Channel Analysis

On the basis of distribution channel, the market is segmented into online pharmacies, hospital pharmacies, and retail pharmacies.

The retail pharmacies segment held a dominant share of the U.S. market in 2022. The segment’s dominance was attributed to the increased demand for diabetes drugs among the population due to high disease prevalence across the nation. Moreover, increasing the presence of these prescription drugs by launching them across retail stores and pharmacies will further propel the segment’s growth.

• According to an article published by CNBC LLC., in August 2023, the demand for prescription diabetes drugs increased among retailers with pharmacy businesses, such as Walmart, Kroger, and Rite Aida, owing to high demand across the nation.


• According to an article published by Walmart, Inc. in June 2021, the retail giant announced the launch of the NovoLog Insulin (analog insulin) through its private ReliOn brand in the U.S.

List of Key Companies in U.S. Diabetes Drugs Market

Novo Nordisk A/S Dominates the Market due to Extensive Diabetes Drugs Portfolio 

The U.S. market is highly concentrated due to the presence of major players, such as Novo Nordisk A/S, Sanofi, and Lilly. Novo Nordisk A/S is estimated to dominate the market during the forecast timeframe owing to its extensive diabetes drugs portfolio and increasing emphasis on the production and launch of advanced drugs in the U.S. market.

• In January 2023, the U.S. FDA approved Novo Nordisk’s oral drug for diabetes, Rybelsus, as an initial treatment to lower blood sugar levels.

Other major players, such as Sanofi and Lilly held a significant U.S. diabetes drugs market share owing to their high focus on mergers and acquisitions of other industry players with significant diabetes drug portfolios in the country. Other significant players operating in this market are Novartis AG, Boehringer Ingelheim International GmbH, AstraZeneca, Merck & Co., Inc., and others.

LIST OF KEY COMPANIES PROFILED:

• Novo Nordisk A/S (Denmark)


• Sanofi (France)


• Merck & Co., Inc. (U.S.)


• Lilly (U.S.)


• AstraZeneca (U.K.)


• Takeda Pharmaceutical Company Limited (Japan)


• Boehringer Ingelheim International GmbH (Germany)


• Novartis AG (Switzerland)


• Johnson & Johnson Services, Inc. (U.S.)


• Bayer AG (Germany)

KEY INDUSTRY DEVELOPMENTS:

• March 2023: Sanofi announced the acquisition of Provention Bio Inc., which will add TZIELD, the disease-modifying treatment used to delay Stage 3 type 1 diabetes (T1D), to Sanofi’s diabetes treatment portfolio.


• January 2023: The U.S. Food and Drug Administration (FDA) approved bexagliflozin (Brenzavvy) by TheracosBio for treating patients with type 2 diabetes.


• January 2020: The FDA approved Trijardy XR (empagliflozin/linagliptin/metformin hydrochloride extended-release tablets) manufactured by Lilly to lower blood sugar in adults with type 2 diabetes.

REPORT COVERAGE

The report provides a detailed analysis of the market. It focuses on key aspects, such as an overview of the prevalence of diabetes in the U.S., drug class, product launches, key industry developments, such as mergers, partnerships, acquisitions, and the impact of COVID-19 on the market. Besides this, it also offers insights into the market trends and highlights key industry dynamics. In addition to the aforementioned factors, the report encompasses several factors that have contributed to the growth of the market in recent years.

Report Scope & Segmentation